Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients

Circulation. 1999 Sep 28;100(13):1400-5. doi: 10.1161/01.cir.100.13.1400.

Abstract

Background: In essential hypertension, endothelium-dependent vasodilation is impaired because of reduced nitric oxide (NO) availability, which is mainly caused by oxidative stress. The present study was designed to identify the mechanism(s) responsible for NO-independent vasodilation to bradykinin in patients with essential hypertension.

Methods and results: In 16 healthy subjects (49.5+/-5.8 years; 118.6+/-3.5/78.9+/-2.9 mm Hg) and 16 patients with essential hypertension (47.9+/-4.8 years; 154.6+/-4.5/102.9+/-3.2 mm Hg), we measured modifications in forearm blood flow (strain-gauge plethysmography) during intrabrachial infusion of bradykinin (5, 15, or 50 ng/100 mL of forearm tissue per minute) in the presence of saline, N(omega)-monomethyl-L-arginine (L-NMMA; used to inhibit NO synthase; 100 microg/100 mL of forearm tissue per minute), and ouabain (to block Na(+)K(+)/ATPase and prevent hyperpolarization; 0.7 microg/100 mL of forearm tissue per minute). In healthy subjects, vasodilatation to bradykinin was significantly blunted by L-NMMA and unaffected by ouabain. In hypertensive patients, vasodilatation to bradykinin was not modified by L-NMMA, but it was significantly reduced by ouabain. In an adjunctive group of 8 hypertensive patients (49.9+/-3.8 years; 155.9+/-5.5/103.7+/-3.9 mm Hg), the response to bradykinin was repeated during the administration of intrabrachial vitamin C (a scavenger for oxygen free radicals; 8 mg/100 mL of forearm tissue per minute). In these patients, L-NMMA-induced inhibition of vasodilation to bradykinin was restored, and ouabain was no longer effective. In a final group of 6 normotensive controls (45.9+/-4.1 years; 115.1+/-2.9/79.3+/-2.1 mm Hg), vasodilation to bradykinin residual to L-NMMA blockade was further inhibited by simultaneous ouabain infusion.

Conclusions: Vasodilation to bradykinin is impaired in essential hypertensive patients because of an NO-system alteration caused by oxidative stress, and it is mediated by an alternative pathway, possibly involving endothelium-dependent hyperpolarization.

MeSH terms

  • Adaptation, Physiological*
  • Adult
  • Antioxidants / pharmacology
  • Ascorbic Acid / pharmacology
  • Biological Availability
  • Bradykinin / pharmacology*
  • Drug Combinations
  • Enzyme Inhibitors / pharmacology*
  • Female
  • Humans
  • Hypertension / metabolism
  • Hypertension / physiopathology*
  • Male
  • Middle Aged
  • Nitric Oxide / metabolism*
  • Nitroprusside / pharmacology
  • Ouabain / pharmacology*
  • Reference Values
  • Vasodilation*
  • Vasodilator Agents / pharmacology*
  • omega-N-Methylarginine / pharmacology

Substances

  • Antioxidants
  • Drug Combinations
  • Enzyme Inhibitors
  • Vasodilator Agents
  • Nitroprusside
  • omega-N-Methylarginine
  • Nitric Oxide
  • Ouabain
  • Ascorbic Acid
  • Bradykinin